Kogenate

Kogenate Uses, Dosage, Side Effects, Food Interaction and all others data.

Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells

Antihemophilic Factor binds factor IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.

Kogenate
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Kogenate
Generic	Antihemophilic factor, human recombinant
Antihemophilic factor, human recombinant Other Names	Antihemophilic factor (recombinant), Antihemophilic factor recombinant, Antihemophilic factor, human recombinant, Antihemophilic factor, recombinant, Coagulation factor VIII, recombinant, Factor VIII (rDNA), Factor VIII (Recombinant), Factor VIII recombin, Factor VIII, recombinant, Human Factor VIII (Recombinant), Human factor VIII recombinant, Octocog alfa, rAHF, Recombinant antihemophilic factor VIII
Type
Formula	C₁₁₇₉₄H₁₈₃₁₄N₃₂₂₀O₃₅₅₃S₈₃
Weight	264725.5 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Kogenate is a form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency.

For the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.

Kogenate is also used to associated treatment for these conditions: Bleeding, Hemophilia A, Perioperative Blood Loss, Bleeding in invasive procedures, Perioperative procedures

How Kogenate works

Antihemophilic factor (AHF) is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A (classical hemophilia).